{"entity":{"id":"blue-earth-therapeutics","kind":"company","name":"Blue Earth Therapeutics","aka":[],"tldr":"Blue Earth Therapeutics makes radioactive drugs that seek out a protein on prostate cancer cells (PSMA), for men whose cancer has spread and no longer responds to hormone treatment. Its lutetium-177 medicine is in a phase 2 trial, and an actinium-225 version entered its first human trial in 2026.","summary":"Blue Earth Therapeutics Ltd (Oxford Science Park, UK) was established by Bracco Imaging in 2021 to develop radioligand therapies based on radiohybrid PSMA (rhPSMA) chemistry. Its first outside financing, a USD 76.5 million Series A, was announced on 30 October 2024, led by Soleus Capital and co-led by Sands Capital Management, with Bracco Imaging, Woodline Partners and PBM Capital. The lead candidate, lutetium (177Lu) rhPSMA-10.1, reported key phase 1 results in March 2025 and began a phase 2 trial in metastatic castration-resistant prostate cancer in May 2025, with the first UK patients dosed in January 2026; it received a UK MHRA Innovation Passport in 2022. The alpha-emitting actinium (225Ac) rhPSMA-10.1, manufactured with Seibersdorf Labor, dosed its first phase 1 participant in July 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.blueearththerapeutics.com/"},{"label":"Series A press release","url":"https://www.prnewswire.com/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290606.html"},{"label":"Pipeline","url":"https://www.blueearththerapeutics.com/pipeline"},{"label":"News","url":"https://www.blueearththerapeutics.com/news"}],"tags":[],"related":["blue-earth-diagnostics"],"cancers":["prostate-mcrpc","prostate"],"sections":["radiopharma"],"technologies":["lu177-radioligand-therapy","radioligand-therapy","targeted-alpha-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Included because the October 2024 Series A was its first announced outside financing; the company was set up by Bracco Imaging in 2021 (per the Series A release) and was already in the clinic before the round. The website does not state a founding year, so `founded` is omitted. Trial dates are from the company's news page."],"hq":"Oxford","country":"GB","companyType":"radiopharma","website":"https://www.blueearththerapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2024,"amountUsd":76500000,"source":"https://www.prnewswire.com/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290606.html"}]},"route":"/companies/blue-earth-therapeutics/","neighbours":{"company":[{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/"}],"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}]}}